Esperion Therapeutics Plunges 17.83% Amid Cautious Outlook

On April 4, 2025, Esperion Therapeutics, Inc. (ESPR) experienced a significant drop of 17.83% in pre-market trading, reflecting a notable decline in investor sentiment.

Esperion Therapeutics has been assigned a Zacks Rank #3 (Hold), indicating that analysts expect the stock to perform in line with the broader market over the next few months. This rating suggests a cautious outlook, with no strong buy or sell signals.

The company's short interest stands at 28.90 million shares, representing 14.87% of the float. This high level of short interest could indicate that some investors are betting against the stock, potentially contributing to the recent price decline.

Esperion Therapeutics is expected to report its next earnings release on May 6, 2025. Analysts anticipate the company to report earnings of -$0.18 per share, which could further influence the stock's performance in the coming weeks.

Despite the recent drop, Esperion Therapeutics has shown strong revenue growth, with a year-over-year increase of 114.30%. The company's gross margin stands at 62.91%, indicating a healthy profit margin. However, the stock's price-to-sales ratio of 0.83x suggests that it may be undervalued relative to its sales.